Rigontec Blog MSD to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology

KENILWORTH, N.J. & MUNICH, GERMANY, Sept. 6, 2017 - MSD (tradename of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK)), and Rigontec today announced that MSD will acquire Rigontec. Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach [...]